Mesa Laboratories, Inc. (NASDAQ:MLAB) Director Robert V. Dwyer sold 5,000 shares of Mesa Laboratories stock in a transaction dated Wednesday, June 20th. The stock was sold at an average price of $210.03, for a total value of $1,050,150.00. Following the completion of the transaction, the director now owns 63,421 shares of the company’s stock, valued at approximately $13,320,312.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Mesa Laboratories opened at $199.97 on Friday, MarketBeat Ratings reports. Mesa Laboratories, Inc. has a 1 year low of $122.35 and a 1 year high of $211.55. The company has a market cap of $769.38 million, a price-to-earnings ratio of 61.40 and a beta of 0.47. The company has a quick ratio of 1.32, a current ratio of 1.85 and a debt-to-equity ratio of 0.45.
Mesa Laboratories (NASDAQ:MLAB) last announced its earnings results on Tuesday, June 5th. The medical instruments supplier reported $1.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.84 by $0.24. Mesa Laboratories had a positive return on equity of 12.93% and a negative net margin of 3.08%. The business had revenue of $26.88 million during the quarter, compared to analyst estimates of $25.40 million. analysts anticipate that Mesa Laboratories, Inc. will post 6.84 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the business. MetLife Investment Advisors LLC purchased a new position in shares of Mesa Laboratories during the fourth quarter valued at approximately $183,000. Capital Analysts LLC boosted its position in shares of Mesa Laboratories by 83.7% during the fourth quarter. Capital Analysts LLC now owns 1,580 shares of the medical instruments supplier’s stock valued at $271,000 after buying an additional 720 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Mesa Laboratories during the first quarter valued at approximately $255,000. Envestnet Asset Management Inc. boosted its position in shares of Mesa Laboratories by 30.2% during the first quarter. Envestnet Asset Management Inc. now owns 2,051 shares of the medical instruments supplier’s stock valued at $304,000 after buying an additional 476 shares during the period. Finally, Keybank National Association OH boosted its position in shares of Mesa Laboratories by 13.2% during the fourth quarter. Keybank National Association OH now owns 3,850 shares of the medical instruments supplier’s stock valued at $479,000 after buying an additional 450 shares during the period. Institutional investors and hedge funds own 73.68% of the company’s stock.
Several research firms recently commented on MLAB. BidaskClub upgraded Mesa Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, June 8th. ValuEngine upgraded Mesa Laboratories from a “hold” rating to a “buy” rating in a research report on Wednesday, June 6th. Finally, Zacks Investment Research upgraded Mesa Laboratories from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th.
About Mesa Laboratories
Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.